Cargando…
Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit
OBJECTIVE: To explore the efficacy and safety of vancomycin as measured by pharmacokinetic/pharmacodynamic parameters in children with severe infection in the Pediatric Intensive Care Unit (PICU) and to determine the appropriate threshold for avoiding nephrotoxicity. METHODS: The medical records of...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279905/ https://www.ncbi.nlm.nih.gov/pubmed/35844752 http://dx.doi.org/10.3389/fped.2022.867712 |
_version_ | 1784746509137346560 |
---|---|
author | Zhou, Bo Xiong, Wenyi Bai, Ke Dang, Hongxing Li, Jing Xu, Feng Fu, Yue-qiang Liu, Chengjun |
author_facet | Zhou, Bo Xiong, Wenyi Bai, Ke Dang, Hongxing Li, Jing Xu, Feng Fu, Yue-qiang Liu, Chengjun |
author_sort | Zhou, Bo |
collection | PubMed |
description | OBJECTIVE: To explore the efficacy and safety of vancomycin as measured by pharmacokinetic/pharmacodynamic parameters in children with severe infection in the Pediatric Intensive Care Unit (PICU) and to determine the appropriate threshold for avoiding nephrotoxicity. METHODS: The medical records of hospitalized children with severe infection treated with vancomycin in the PICU of a tertiary pediatric hospital from September 2018 to January 2021 were retrospectively collected. Univariate analysis was used to assess the correlation between vancomycin pharmacokinetic/pharmacodynamic parameters and therapeutic efficacy or vancomycin-related nephrotoxicity. Binary logistic regression was used to analyze the risk factors for vancomycin-related nephrotoxicity. The vancomycin area under the concentration-time curve over 24 h (AUC(0–24)) threshold was determined by receiver operating characteristic (ROC) curve analysis. RESULTS: One hundred and 10 patients were included in this study. Seventy-six patients (69.1%) exhibited clinically effective response, while the rest exhibited clinically ineffective response. There were no significant differences in APACHE II score, steady-state trough concentration, peak concentration or AUC(0–24) of vancomycin between the effective and ineffective groups. Among the 110 patients, vancomycin-related nephrotoxicity occurred in 15 patients (13.6%). Multivariate analysis showed that vancomycin treatment duration, trough concentration, and AUC(0–24) were risk factors for vancomycin-related nephrotoxicity. The ROC curve indicated that AUC(0–24) < 537.18 mg.h/L was a suitable cutoff point for predicting vancomycin-related nephrotoxicity. CONCLUSION: No significant correlations were found between the trough concentration or AUC(0–24) of vancomycin and therapeutic efficacy when the daily dose of vancomycin was approximately 40 mg/kg d, while the trough concentration and AUC(0–24) were both closely related to vancomycin-related nephrotoxicity. The combination of AUC(0–24) and trough concentration for therapeutic drug monitoring may reduce the risk of nephrotoxicity. |
format | Online Article Text |
id | pubmed-9279905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92799052022-07-15 Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit Zhou, Bo Xiong, Wenyi Bai, Ke Dang, Hongxing Li, Jing Xu, Feng Fu, Yue-qiang Liu, Chengjun Front Pediatr Pediatrics OBJECTIVE: To explore the efficacy and safety of vancomycin as measured by pharmacokinetic/pharmacodynamic parameters in children with severe infection in the Pediatric Intensive Care Unit (PICU) and to determine the appropriate threshold for avoiding nephrotoxicity. METHODS: The medical records of hospitalized children with severe infection treated with vancomycin in the PICU of a tertiary pediatric hospital from September 2018 to January 2021 were retrospectively collected. Univariate analysis was used to assess the correlation between vancomycin pharmacokinetic/pharmacodynamic parameters and therapeutic efficacy or vancomycin-related nephrotoxicity. Binary logistic regression was used to analyze the risk factors for vancomycin-related nephrotoxicity. The vancomycin area under the concentration-time curve over 24 h (AUC(0–24)) threshold was determined by receiver operating characteristic (ROC) curve analysis. RESULTS: One hundred and 10 patients were included in this study. Seventy-six patients (69.1%) exhibited clinically effective response, while the rest exhibited clinically ineffective response. There were no significant differences in APACHE II score, steady-state trough concentration, peak concentration or AUC(0–24) of vancomycin between the effective and ineffective groups. Among the 110 patients, vancomycin-related nephrotoxicity occurred in 15 patients (13.6%). Multivariate analysis showed that vancomycin treatment duration, trough concentration, and AUC(0–24) were risk factors for vancomycin-related nephrotoxicity. The ROC curve indicated that AUC(0–24) < 537.18 mg.h/L was a suitable cutoff point for predicting vancomycin-related nephrotoxicity. CONCLUSION: No significant correlations were found between the trough concentration or AUC(0–24) of vancomycin and therapeutic efficacy when the daily dose of vancomycin was approximately 40 mg/kg d, while the trough concentration and AUC(0–24) were both closely related to vancomycin-related nephrotoxicity. The combination of AUC(0–24) and trough concentration for therapeutic drug monitoring may reduce the risk of nephrotoxicity. Frontiers Media S.A. 2022-06-30 /pmc/articles/PMC9279905/ /pubmed/35844752 http://dx.doi.org/10.3389/fped.2022.867712 Text en Copyright © 2022 Zhou, Xiong, Bai, Dang, Li, Xu, Fu and Liu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Zhou, Bo Xiong, Wenyi Bai, Ke Dang, Hongxing Li, Jing Xu, Feng Fu, Yue-qiang Liu, Chengjun Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit |
title | Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit |
title_full | Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit |
title_fullStr | Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit |
title_full_unstemmed | Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit |
title_short | Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit |
title_sort | clinical application value of pharmacokinetic parameters of vancomycin in children treated in the pediatric intensive care unit |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279905/ https://www.ncbi.nlm.nih.gov/pubmed/35844752 http://dx.doi.org/10.3389/fped.2022.867712 |
work_keys_str_mv | AT zhoubo clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit AT xiongwenyi clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit AT baike clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit AT danghongxing clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit AT lijing clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit AT xufeng clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit AT fuyueqiang clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit AT liuchengjun clinicalapplicationvalueofpharmacokineticparametersofvancomycininchildrentreatedinthepediatricintensivecareunit |